Skip to main content
GENETIC TECHNOLOGIES LIMITED logo

GENETIC TECHNOLOGIES LIMITED — Investor Relations & Filings

Ticker · GTG ISIN · AU000000GTG7 LEI · 529900YYKY7FRC90M744 ASX Human health and social work activities
Open in API
Filings indexed 1,303 across all filing types
Latest filing 2010-05-09 Regulatory Filings
Country AU Australia
Listing ASX GTG

About GENETIC TECHNOLOGIES LIMITED

https://gtglabs.com/

Genetic Technologies Limited is a molecular diagnostics company focused on the development and commercialization of predictive genetic risk assessment tools. The company specializes in the geneType platform, which integrates clinical risk factors with polygenic risk scores to provide comprehensive risk assessments for various chronic diseases. Its portfolio includes tests for breast cancer, colorectal cancer, prostate cancer, melanoma, type 2 diabetes, and coronary artery disease. By identifying individuals at high risk of developing these conditions, the company enables healthcare providers to implement personalized screening and preventative health strategies. Genetic Technologies Limited serves clinicians and patients globally, aiming to improve health outcomes through early detection and precision medicine.

Recent filings

Filing Released Lang Actions
Patent claims upheld in full by USPTO 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated May 10, 2010, regarding the United States Patent and Trademark Office (USPTO) upholding all claims of a specific patent held by Genetic Technologies Limited. It discusses the patent re-examination outcome, previous legal actions, and the company's patent assertion program. There is no financial data, no mention of financial results, no management or board changes, no shareholder voting results, no regulatory certifications, or other report types. The document is a formal announcement of a patent-related legal and business development. It is not a report, transcript, or financial filing. Therefore, the best fitting category is a Regulatory Filing (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2010-05-09 English
GTG grants license to EraGen Biosciences 1 page ?Kb
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated May 5, 2010, regarding Genetic Technologies Limited granting a non-coding license to EraGen Biosciences. It discusses a Settlement and License Agreement and commercial terms related to patent licensing. There is no indication of financial statements, management discussion, or regulatory certifications. The content is a corporate announcement about licensing activity, not a financial report or regulatory filing. The document length is 2862 characters, which is relatively short and consistent with an announcement rather than a detailed report. Therefore, the document fits best under Capital/Financing Update (CAP) as it relates to licensing agreements and commercial terms affecting company assets and intellectual property.
2010-05-04 English
GTG grants non-coding license to Gen-Probe 1 page ?
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated May 3, 2010, regarding a Settlement and License Agreement between Genetic Technologies Limited and Gen-Probe Inc. It discusses the granting of a license related to non-coding patents and mentions a previously announced patent infringement suit. The content focuses on a licensing agreement and settlement, which is a capital or financing-related update rather than a full financial report, earnings release, or management discussion. The document is relatively short (3007 characters) and is an announcement of a business agreement rather than a detailed report or financial statement. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2010-05-02 English
Appendix 4C - quarterly 9 pages ?Kb
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Activities Report and Appendix 4C of the ASX Listing Rules for the quarter ended 31 March 2010'. It contains detailed operational updates, acquisition information, licensing and IP updates, research and development progress, corporate matters including share issuance, and a detailed Appendix 4C which is a quarterly report format under ASX rules. The document includes financial data such as cash flows, payments to directors, and financing facilities, all for the quarter ended 31 March 2010. This matches the characteristics of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year and contains substantive financial data and analysis. The document is about 15,000 characters long, so it is not a brief announcement or a report publication notice. Therefore, the correct classification is Interim / Quarterly Report (IR). Q3 2010
2010-04-27 English
Signed Notice of Initial Substantial Shareholder 2 pages ?Kb
Major Shareholding Notification Classification · 100% confidence The document is a Form 603 under the Corporations Act 2001 Section 671B, which is a Notice of Initial Substantial Holder. It details the substantial shareholding of James Edward Besser in Genetic Technologies Limited, including voting power, relevant interests, registered holders, and consideration paid. This type of filing is a notification of a major shareholding change, not a financial report, management update, or other corporate filing. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length is short and focused solely on shareholding details, confirming this classification.
2010-04-14 English
Acquisition of BREVAGen 3 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated April 14, 2010, regarding Genetic Technologies Limited's acquisition of assets from Perlegen Sciences, Inc., specifically the BREVAGen™ breast cancer risk test and related patents. The content focuses on the acquisition details, product description, market potential, and company strategy. There are no financial statements, quarterly or annual results, nor any regulatory certifications or voting results. The document is a corporate announcement about an asset acquisition and business update, which fits best under Capital/Financing Update (CAP) as it relates to acquisition of assets and expansion of the company's portfolio. The document length (8251 characters) and content confirm it is not a brief report publication announcement or a regulatory filing. Therefore, the classification is CAP with high confidence.
2010-04-13 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.